CLINICAL_TRIALS
trial_result
· 2021-03-19
Clinical Trial Update: Aurinia Early Urinary Protein Reduction Predicts Response [Phase 2]
Summary
Phase 2 trial update suggests that early reduction in urinary protein predicts response in lupus nephritis.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Snippet
Sponsor: Aurinia Pharmaceuticals Inc. | Conditions: Lupus Nephritis | Phase 2 | Status: COMPLETED | Results posted: 2021-03-19